Previous 10 | Next 10 |
2023-06-26 17:20:36 ET Gainers: Terns Pharmaceuticals ( NASDAQ: TERN ) +7% . Savara ( SVRA ) +5% . Nkarta ( NKTX ) +5% . COMPASS Pathways ( CMPS ) +3% . Matterport ( MTTR ) +2% . Losers: Adicet ( ACET ...
Last week, a federal health agency requested that studies into the influence of evolving laws on psychedelics in states and cities across the country be conducted. The National Institute on Drug Abuse (NIDA) issued a notice talking about how the psychedelic reform movement had spread and discus...
LONDON, June 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the following investor conferences: Cantor Fitzger...
Researchers from Compass Pathways PLC (NASDAQ: CMPS) have commenced the largest-ever phase 3 clinical trial investigating the effectiveness of psilocybin against depression. The mental health company first announced the phase 3 program in late 2022 during an online Capital Markets Day. Comp...
PTAB rejects two requests for rehearing of the USPTO's decision denying institution of post-grant review (PGR) of U.S. patent numbers 10,947,257 (‘257 Patent) and 10,954,259 (‘259 Patent). In June 2022, the PTAB denied institution of the PGRs finding the challenger failed to...
For the longest time, the field of palliative care has been focused on making seriously or terminally ill patients as physically comfortable as possible for the time they have left. This often includes medication to relieve pain, treatments such as surgery and radiation therapy to treat symptoms ...
LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will s...
LONDON, May 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Jefferies Healthcare Conference at 3:30 pm ET ...
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological support Open label phase 2 study, conducted by Sunstone Therapies and scheduled to be presented at the ASCO annual meeting on...
A surge in psychedelic research in recent years has revealed something quite interesting: several psychedelic drugs are capable of alleviating symptoms of mental disorders with relatively few side effects. Dubbed the psychedelic renaissance , this movement has seen dozens of researchers across...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...